Escolar Documentos
Profissional Documentos
Cultura Documentos
Original Article
Abstract
Editorial Viewpoint
This is a retrospective
dose finding study of
pioglitazone on glycemic
control and weight gain in
type 2 diabetes mellitus.
Introduction
Department of Diabetology and Endocrinology, Lilavati Hospital Mumbai and Department of Medicine, KJ
Somaiya Medical College, Mumbai, Maharashtra; 2Dr Panikars Speciality Care Centre, Mumbai, Maharashtra;
3
Department of Pharmacy, Narsee Monjee Institute of Management Studies (NMIMS) University, Mumbai,
Maharashtra; 4Joshi Clinic and Department of Diabetology and Endocrinology, Lilavati Hospital, Mumbai,
Maharashtra; 5Dr. Narayan Deogaonkars Hospital, Nashik, Maharashtra
Received: 17.08.2015; Accepted: 23.08.2015
1
Group A
No. of pts.
77
Male %
41/77 (52.6%)
Age (years)
58.23 (10.96)
DM diagnosis (mths) 6.65 (4.17)
Height (cm)
163.79 (6.6)
Weight (kg)
74.03 (15.27)
27.63 (5.51)
BMI (kg/m2)
HbA1c (%)
7.44 (0.57)
Group B
80
45/80 (56.3%)
56.64 (10.56)
5.99 (5.64)
162.15 (9.12)
69.68 (12.41)
26.62 (4.91)
7.60 (0.40)
37
Parameter
Group A
Weight (kg)
74.98 15.94
Weight change +0.88 2.77
27.96 5.63
BMI (kg/m2)
BMI change
+0.33 1.01
HbA1c (%)
6.2 0.39
% reduction
1.24 0.65
Group B
71.47 12.55
+1.62 2.91
27.60 5.60
+0.62 1.10
6.3 0.46
1.18 0.59
Group C
P value
71.56 13.53 0.218
+2.72 2.97 <0.001
27.10 5.18
0.429
+1.03 1.14 <0.001
6.5 0.38
<0.001
1.25 0.84
0.813
Statistical Analysis
Results
The baseline characteristics of
patients are enlisted in Table 1.
The differences in age (A vs B:
P=0.580; A vs C: P=0.016; B vs C:
P=0.173) and baseline HbA1c (A
vs B: P=0.198; A vs C: P=0.002; B
vs C: P=0.173) were significant
between the groups. There was a
borderline significant difference
in baseline weight, though there
was no corresponding difference in
the baseline BMI. All patients were
Asian Indians and our study group
did not include patients from any
other racial or ethnic background.
Characteristics of patients at the
end of six months are shown in
Table 2. At the end of six months,
a significant increase in weight (A:
P=0.007; B: P<0.001; C: P<0.001)
38
Discussion
Pioglitazone has been used
globally for over two decades. It has
proven efficacy as an antidiabetic
and is especially valued in the
AsianIndian patients, who have
a high level of insulin resistance. 4
In India, for many patients with
diabetes, pioglitazone being an
insulin sensitizer, comes as an
agent that can delay the need of
initiation of insulin therapy for
years together. 5
Our study aimed to assess the
effect of different daily doses
of pioglitazone on glycemic
control and weight gain in newly-
2011; 15:294-7.
2.
3.
4.
5.
6.
7.
8.
9.
Conclusions
The glycemic effect of
pioglitazone is preserved
even at lower doses, while the
propensity to cause weight gain
increases with dose. We suggest
that low-dose pioglitazone (7.5
mg/day) should be the preferred
dose at which to initiate therapy
in recently-diagnosed patients.
Pioglitazone is an extremely useful
agent in the treatment of type 2
diabetes mellitus (DM) through
its actions on alleviating insulin
resistance.
Acknowledgements
This study was presented as
an abstract at the International
Diabetes Federation 20 th World
Diabetes Congress, Montreal,
Canada (October 18-22, 2009).
Financial support: None
References
1.
39